Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease

2004 ◽  
Vol 19 (12) ◽  
pp. 1403-1408 ◽  
Author(s):  
Padraig E. O'Suilleabhain ◽  
Teodoro Bottiglieri ◽  
Richard B. Dewey ◽  
Shailja Sharma ◽  
Ramon Diaz-Arrastia
Author(s):  
Stefano Zoccolella ◽  
Paolo Lamberti ◽  
Giovanni Iliceto ◽  
Cosimo Diroma ◽  
Elio Armenise ◽  
...  

AbstractElevated plasma homocysteine (Hcy) concentrations are associated with Alzheimer's disease and vascular dementia. Several recent reports have indicated that L-dopa treatment is an acquired cause of hyperhomo-cysteinemia. Despite the fact that a large proportion of Parkinson's disease (PD) patients develop cognitive dysfunctions or dementia, particularly in the late stages of the illness and after long-term L-dopa treatment, the relationship between Hcy and dementia in PD has not been fully investigated. The aim of this study was to evaluate plasma Hcy levels in a group of L-dopa-treated PD patients with cognitive impairment and to elucidate a possible role of Hcy in the development of cognitive dysfunctions in PD. We compared Hcy, vitamin B


2010 ◽  
Vol 31 (5) ◽  
pp. 565-569 ◽  
Author(s):  
Martin Nevrly ◽  
Petr Kanovsky ◽  
Hana Vranova ◽  
Katerina Langova ◽  
Petr Hlustik

2009 ◽  
Vol 15 (6) ◽  
pp. 477-478 ◽  
Author(s):  
M. Nevrly ◽  
P. Kanovsky ◽  
H. Vranova ◽  
K. Langova ◽  
P. Hlustik

Author(s):  
Stefano Zoccolella ◽  
Paolo Lamberti ◽  
Giovanni Iliceto ◽  
Claudia Dell'Aquila ◽  
Cosimo Diroma ◽  
...  

AbstractClin Chem Lab Med 2006;44:863–6.


Sign in / Sign up

Export Citation Format

Share Document